There is one clinical trial.
To test the patient's cancerous tumor to see if it has a FGFR mutation and, if so, to see how their cancer responds to a treatment with the drug ponatinib as well as examine the side effects caused by ponatinib.
Activating mutations are defined as the known FGFR2 hotspots at S252W, P253R, S373C, Y376C, C383R, N550K, N550H, K660E. --- S252W --- --- P253R --- --- S373C ---
Description: Ponatinib in patients with recurrent or persistent endometrioid endometrial cancer (FGFR2 activating mutation positive)for tumor responses (CR + PR) Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Measure: Tumor responses (CR + PR) Time: 6 monthsDescription: Ponatinib in patients with recurrent or persistent endometrioid endometrial cancer (FGFR2 activating mutation positive) by evaluating progression-free survival Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Measure: Progression Free survival Time: 6 monthsDescription: Progression Free Survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Measure: Progression Free Survival Time: 5.5 yearsDescription: Overall survival is define as date from time of initial treatment to date of death from any cause.
Measure: overall survival Time: 5.5 yearsDescription: Frequency and severity as defined by CTCAE v 4.0
Measure: Toxicity of Ponatinib Time: 1 year